RFI-641, a potent respiratory syncytial virus inhibitor

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 3, 2002, Pages 841-847

  Huntley, Clayton C ^a   Weiss, William J ^a   Gazumyan, Anna ^a   Buklan, Aron ^a   Feld, Boris ^a   Hu, William ^a   Jones, Thomas R ^a   Murphy, Timothy ^a   Nikitenko, Antonia A ^a   O'Hara, Bryan ^a   Prince, Gregory ^a   Quartuccio, Susan ^a   Raifeld, Yuri E ^a   Wyde, Philip ^a   O'Connell, John F ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,4' BIS[4,6 BIS[3 (BIS CARBAMOYLMETHYLSULFAMOYL)PHENYLAMINO] (1,3,5) TRIAZIN 2 YLAMINO]BIPHENYL 2,2' DISULFONIC ACID; ANTIVIRUS AGENT; RFI 641; UNCLASSIFIED DRUG; VIRUS F PROTEIN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CERCOPITHECIDAE; CHILDHOOD DISEASE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; FEMALE; HUMAN; INFANT DISEASE; LOWER RESPIRATORY TRACT INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS A; RESPIRATORY SYNCYTIAL VIRUS B; STRAIN DIFFERENCE; UPPER RESPIRATORY TRACT INFECTION; VIRUS INHIBITION; VIRUS TYPING;

ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CYTOMEGALOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MALE; MICE; MICE, INBRED BALB C; PLAQUE ASSAY; RATS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SIGMODONTINAE; SULFONAMIDES; TEMPERATURE; TRIAZINES; VIRUS REPLICATION;

EID: 0036170138     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.3.841-847.2002     Document Type: Article

References (31)

1. Inhibition of respiratory syncytial virus by a new class of chemotherapeutic agents
2. Ribavirin therapy of adult respiratory syncytial virus pneumonitis
3. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse
4. Novel and specific respiratory syncytial virus inhibitors that target virus fusion
5. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults
6. Respiratory syncytial virus infection in adults
7. Novel anti-RSV dianionic dendrimer-like compounds: Design, synthesis and biologic evaluation
8. Respiratory syncytial virus: A continuing culprit and conundrum
9. Analysis of respiratory syncytial virus F, G, and SH proteins in cell fusion
10. Respiratory syncytial virus SH and G proteins are not essential for viral replication in vitro: Clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant
11. Experimental models for respiratory syncytial virus infections
12. Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells
13. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion
14. Respiratory syncytial virus puzzle: Clinical features, pathophysiology, treatment and prevention
15. Clinical profile of pediatric patients hospitalized with respiratory syncytial virus infection
16. Heptad-repeat regions of respiratory syncytial virus F1 protein form a six-membered coiled-coil complex
17. The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil
18. Respiratory syncytial virus
19. The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus
20. Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection
21. A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3
22. The pathogenesis of respiratory syncytial virus infection in cotton rats
23. RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein
24. Recent progress in antiviral chemotherapy for respiratory syncytial virus infections
25. Mouse model of respiratory syncytial virus infection to evaluate antiviral activity in vivo
26. Monoclonal antibodies to respiratory syncytial virus proteins: Identification of the fusion protein
27. A synthetic peptide from HIV-1 GP-41 is a potent inhibitor of virus mediated cell-cell fusion
28. Respiratory syncytial virus (RSV) disease and prospects for its control
29. CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats
30. Structural characterization of the human respiratory syncytial virus fusion protein core
31. Comparison of 3H-thymidine incorporation and CellTiter 96 aqueous colorimetric assays in cell proliferation of bovine mononuclear cells